Recent preclinical studies on dual targeting of acute myeloid leukemia with a transgenic NPM1-antigen-specific TCR and a CD33 CAR revealed that double transgenic receptor expression led to better cytotoxicity and tumor control relative to single receptor-expressing T cells (158). This evidence concerns the gene CD33 and neoplasm.